- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sheila Frame: Biosimilars and Device Design
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the importance of device design for biosimilars.
Transcript:
I think device design is a super exciting area for innovation that biosimilars can actually bring to the marketplace, so especially for Sandoz, because we're part of a larger organization, we have access to some tremendous device technology that we can bring into the marketplace with already having had the experience, right? It's not like we have to start from scratch to create that innovation in terms of device, but we can actually benefit from all the innovation that's happened in the past from other manufacturers and bring that into our biologic products to make sure that patients get exactly what's easy.
I do think it's important. I think there's a big stigma associated with either sitting in an infusion chair for hours or sticking yourself with a needle every day. We see it in diabetes, right? You see it in arthritis now, and there's been some tremendous innovation in terms of those devices. So I think it's a pretty exciting area for us and certainly one that we're always looking for new and better ways to make it easier for patients to not only access their medication, pay for them, and also benefit from the innovations in terms of making it simple.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
